5781-02-2

Basic information

• Product Name: 5-TERT-BUTYL-2-METHYLPHENOL
• Synonyms: 5-TERT-BUTYL-2-METHYLPHENOL;5-tert-butyl-o-cresol;2-Methyl-5-tert-butylphenol;5-(1,1-Dimethylethyl)-2-methylphenol
• CAS NO: 5781-02-2
• Molecular Formula: C₁₁H₁₆O
• Molecular Weight: 164.24
• EINECS: 227-306-9
• Mol File: 5781-02-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 251.73°C (rough estimate)
• Flash Point: 111.6°C
• Appearance: /
• Density: 0.9197 (rough estimate)
• Vapor Pressure: 0.0161mmHg at 25°C
• Refractive Index: 1.5400 (estimate)
• Water Solubility: 416mg/L(25 oC)
• CAS DataBase Reference: 5-TERT-BUTYL-2-METHYLPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-TERT-BUTYL-2-METHYLPHENOL(5781-02-2)
• EPA Substance Registry System: 5-TERT-BUTYL-2-METHYLPHENOL(5781-02-2)

Safety Data

• Hazardous Substances Data: 5781-02-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H16O/c1-8-5-6-9(7-10(8)12)11(2,3)4/h5-7,12H,1-4H3

Upstream product

• 942499-01-6 3-hydroxy-4-methyl-2H-pyran-2-one 
• 20429-42-9 2-(tert-butyl)-1-nitroethene 
• 585-34-2 3-tert-butylphenyol 
• 66232-34-6 4-tert-butyl-2-hydroxybenzaldehyde 
• 174822-06-1 2-hydroxymethyl-5-t-butylphenol 
• 98-51-1 4-tert-butyltoluene 
• 62559-08-4 4-tert-butyl-2-nitrotoluene 
• 85336-17-0 5-tert-butyl-2-methylaniline 

Downstream Products

• 24456-96-0 2-tert-butyl-5-methyl-1,4-benzoquinone 
• 17388-14-6 trans-5-tert.-Butyl-cis-2-methyl-cyclohexanol 
• 18952-28-8 cis-5-tert.-Butyl-cis-2-methyl-cyclohexanol 
• 5937-42-8 cis-5-tert.-Butyl-trans-2-methyl-cyclohexanol 
• 263843-05-6 dimethylsulfamic acid 4-{6-[2-(4-aminophenyl)ethyl]-4-hydroxy-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-5-tert-butyl-2-methylphenyl ester hydrochloride 
• 207737-16-4 5-tert-butyl-4-mercapto-2-methylphenol 
• 207737-17-5 toluene-4-thiosulfonic acid S-(2-tert-butyl-4-hydroxy-5-methylphenyl) ester 
• 207737-20-0 toluene-4-thiosulfonic acid S-(2-tert-butyl-4-dimethylsulfamoyloxy-5-methyl-phenyl) ester 
• 207737-21-1 toluene-4-thiosulfonic acid S-(2-tert-butyl-4-ethylsulfamoyloxy-5-methyl-phenyl) ester 
• 249728-23-2 ethyl-sulfamic acid 5-tert-butyl-4-(4-hydroxy-6-isopropyl-2-oxo-6-phenethyl-5,6-dihydro-2H-pyran-3-ylsulfanyl)-2-methyl-phenyl ester 
• 249728-17-4 dimethyl-sulfamic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester 
• 207736-26-3 ethyl-sulfamic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester 
• 260257-94-1 3-(2-tert-butyl-4-hydroxy-5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-6-phenethyl-5,6-dihydro-pyran-2-one 
• 207737-19-7 dimethylsulfamic acid 5-tert-butyl-4-mercapto-2-methylphenyl ester 

Relevant articles and documents

Synthesis of Highly Substituted Phenols and Benzenes with Complete Regiochemical Control

Substituted phenols are requisite molecules for human health, agriculture, and diverse synthetic materials. We report a chemical synthesis of phenols, including penta-substituted phenols, that accommodates programmable substitution at any position. This method uses a one-step conversion of readily available hydroxypyrone and nitroalkene starting materials to give phenols with complete regiochemical control and in high chemical yield. Additionally, the phenols can be converted into highly and even fully substituted benzenes.

2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS

The present disclosure provides phenolic compounds useful in the treatment of neurological conditions such as convulsions and tremors, having the structure of Formula (I): wherein R2, R4, and R5, are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating neurological conditions.

METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B

The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.